enGene Holdings, a clinical-stage, non-viral genetic medicines company, entered into an amendment to an amended and restated loan and security agreement with two of its subsidiaries and Hercules Capital as agent, for up to US$125 million. Access to...
Read Story
January 21, 2026, 07:32 AM
|
enGene Holdings, a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), entered into an amended USD $50 million loan agreement with Hercules Capital....
Read Story
December 27, 2023, 08:00 AM
|